About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Patients on NSAIDS have reduced gastric ulcers risk by Nexium®

by Medindia Content Team on March 23, 2006 at 7:20 PM
Font : A-A+

Patients on NSAIDS have reduced gastric ulcers risk by Nexium®

Patients on non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective NSAIDs, have reduced risk of gastric ulcers by taking NEXIUM® (esomeprazole magnesium). These results were from from two clinical trials and will be in the April 2006 edition of the American Journal of Gastroenterology.

NSAIDs include traditional, non-selective drugs, such as ibuprofen, naproxen and aspirin, and newer COX-2-selective agents.

Advertisement

The study which was a double-blind, randomized, six-month trial collected data and showed that significantly fewer patients taking either NEXIUM 20 mg or NEXIUM 40 mg, in addition to their regular non-selective NSAID/COX-2-selective therapy, developed an ulcer at six months, compared to those taking a placebo (5.2 percent and 4.6 percent, respectively, vs. 17 percent, p<0.001).

James M. Scheiman, MD, Division of Gastroenterology, Department of Internal Medicine, University of Michigan said, "Paradoxically, NSAID use is common among patients at high risk for gastric ulcers or other complications associated with these medications. Although COX-2-selective drugs generally cause fewer gastric ulcers than non-selective NSAIDs, these events aren't completely eliminated, and the residual side-effect rate still may be high. Data from the two trials showed that NEXIUM was effective in reducing stomach ulcers in at-risk patients who require chronic NSAID treatment."
Advertisement

Data from the two studies which were double-blind, randomized, placebo-controlled trials involved a total of 844 (U.S.) and 585 (multinational) patients. They were randomly assigned in a 1:1:1 ratio to treatment with either NEXIUM 20 mg, NEXIUM 40 mg or a placebo. Patients were continuous NSAID users (i.e., receiving daily non-selective NSAID or COX-2 therapy for at least four weeks before and throughout the duration of the six-month trial) at risk of developing a gastric or duodenal ulcer as a result of older age (>60 years) and/or a history of previous gastric ulcers.

The results were noted and analyzed for the study.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
H1N1 Influenza Prevention in Children: What Parents Need to Know
Dietary Factors Responsible for Dihydrotestosterone (DHT) Production and Hair Loss
Test Your Knowledge About Chromosomes?
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Gastroscopy Peptic Ulcer Indigestion Colon Polyps Acid Peptic Disease Digestive Tract Ulcers Symptom Evaluation 

Most Popular on Medindia

Selfie Addiction Calculator Iron Intake Calculator Blood Pressure Calculator Color Blindness Calculator Blood Donation - Recipients Drug Side Effects Calculator Hearing Loss Calculator Nutam (400mg) (Piracetam) Calculate Ideal Weight for Infants Vent Forte (Theophylline)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Patients on NSAIDS have reduced gastric ulcers risk by Nexium® Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests